

Opko Health, Inc.
Form 8-K
May 05, 2015

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

May 5, 2015

OPKO Health, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-33528

75-2402409

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(I.R.S. Employer
Identification No.)

4400 Biscayne Blvd., Miami, Florida

33137

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code:

(305) 575-4100

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Top of the Form

Item 1.01 Entry Into a Material Definitive Agreement.

On May 5, 2015, OPKO Health, Inc., a Delaware corporation (the **Company**), entered into a series of purchase agreements (the **Agreements**) by and among the Company, OPKO Ireland Limited, an Irish company and a wholly owned subsidiary of the Company (**OPKO Ireland** and together with the Company, the **Buyers**), and the shareholders (the **Sellers**) of EirGen Pharma Limited, a private limited company incorporated in Ireland (**EirGen**).

Pursuant to the **Agreements**, the **Buyers** purchased from the **Sellers** all of the issued and outstanding shares of EirGen for approximately \$135 million in the aggregate. OPKO Ireland acquired a portion of the outstanding shares of EirGen for approximately \$100 million in cash, and the **Company** acquired the remaining outstanding shares of EirGen for approximately \$35 million in shares of the **Company**'s common stock (the **Stock Consideration**). The **Stock Consideration** consisted of 2,420,487 of the **Company**'s shares based on the average closing sales price per share of the **Company**'s Common Stock as reported by the New York Stock Exchange for the ten trading days immediately preceding the execution date of **Agreements**, or \$14.39 per share. Pursuant to the **Agreements**, a portion of the **Stock Consideration** is being held in a separate escrow account to secure the indemnification obligations of principal sellers under the **Agreements**. The **Agreements** contains customary representations, warranties, conditions to closing, indemnification rights and obligations of the parties.

The **Stock Consideration** was issued in reliance upon an exemption from the registration requirements under the Securities Act of 1933, as amended (the **Securities Act**), pursuant to Regulation S in an offshore transaction with non U.S. Persons.

The above description of the **Agreements** does not purport to be complete and is solely intended as a summary of the material terms of the **Agreements**.

Item 2.01 Completion of Acquisition or Disposition of Assets.

On May 5, 2015, the **Buyers** acquired all of the issued and outstanding shares of EirGen. The information reported in Item 1.01 of this Current Report on Form 8-K is hereby incorporated by reference to this Item.

Item 3.02 Unregistered Sales of Equity Securities.

The information reported in Item 1.01 of this Current Report on Form 8-K is hereby incorporated by reference to this Item.

Item 7.01 Regulation FD Disclosure.

On May 5, 2015, the **Company** issued a press release announcing that it entered into the **Agreements**. A copy of the press release is being filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information contained in Item 7.01 to this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed filed for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the **Company** under the Exchange Act.

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OPKO Health, Inc.

May 5, 2015

By: Adam Logal

Name: Adam Logal

Title: Senior Vice President-Chief Financial Officer

Edgar Filing: Opko Health, Inc. - Form 8-K

Top of the Form

Exhibit Index

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release of the Company, dated May 5, 2015